Literature DB >> 19444252

Bone: Use of bisphosphonates in children-proceed with caution.

Joan C Marini.   

Abstract

A clinical review of studies on bisphosphonate therapy for pediatric osteoporosis has revealed that they increase BMD, but whether they also improve fracture rates or functions of daily life is unclear. Can the findings of this clinical review help inform clinicians whether, when and how to use these agents in children?

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19444252     DOI： 10.1038/nrendo.2009.58

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

1.  Bisphosphonate-induced osteopetrosis.

Authors:  Michael P Whyte; Deborah Wenkert; Karen L Clements; William H McAlister; Steven Mumm
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

2.  Should children with osteogenesis imperfecta be treated with bisphosphonates?

Authors:  Joan C Marini
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-01

3.  Economic return of clinical trials performed under the pediatric exclusivity program.

Authors:  Jennifer S Li; Eric L Eisenstein; Henry G Grabowski; Elizabeth D Reid; Barry Mangum; Kevin A Schulman; John V Goldsmith; M Dianne Murphy; Robert M Califf; Daniel K Benjamin
Journal:  JAMA       Date:  2007-02-07       Impact factor: 56.272

4.  Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.

Authors:  Frank Rauch; Rose Travers; Francis H Glorieux
Journal:  J Clin Endocrinol Metab       Date:  2005-11-15       Impact factor: 5.958

5.  Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.

Authors:  Anne D Letocha; Holly L Cintas; James F Troendle; James C Reynolds; Christopher E Cann; Edith J Chernoff; Suvimol C Hill; Lynn H Gerber; Joan C Marini
Journal:  J Bone Miner Res       Date:  2005-01-18       Impact factor: 6.741

6.  Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

Authors:  Matthew R Allen; David B Burr
Journal:  J Bone Miner Res       Date:  2007-11       Impact factor: 6.741

7.  Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases.

Authors:  Michael P Whyte; William H McAlister; Deborah V Novack; Karen L Clements; Perry L Schoenecker; Deborah Wenkert
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

Review 8.  Clinical review 1: Bisphosphonate use in childhood osteoporosis.

Authors:  Laura K Bachrach; Leanne M Ward
Journal:  J Clin Endocrinol Metab       Date:  2008-11-25       Impact factor: 5.958

9.  Giant osteoclast formation and long-term oral bisphosphonate therapy.

Authors:  Robert S Weinstein; Paula K Roberson; Stavros C Manolagas
Journal:  N Engl J Med       Date:  2009-01-01       Impact factor: 91.245

10.  Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.

Authors:  Thomas E Uveges; Kenneth M Kozloff; Jennifer M Ty; Felicia Ledgard; Cathleen L Raggio; Gloria Gronowicz; Steven A Goldstein; Joan C Marini
Journal:  J Bone Miner Res       Date:  2009-05       Impact factor: 6.741
  10 in total
  10 in total

1.  Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.

Authors:  M L Bianchi; L Morandi; E Andreucci; S Vai; J Frasunkiewicz; R Cottafava
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

Review 2.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

3.  Reduced diaphyseal strength associated with high intracortical vascular porosity within long bones of children with osteogenesis imperfecta.

Authors:  Carolyne Albert; John Jameson; Peter Smith; Gerald Harris
Journal:  Bone       Date:  2014-06-11       Impact factor: 4.398

4.  Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta.

Authors:  Jutta Becker; Oliver Semler; Christian Gilissen; Yun Li; Hanno Jörn Bolz; Cecilia Giunta; Carsten Bergmann; Marianne Rohrbach; Friederike Koerber; Katharina Zimmermann; Petra de Vries; Brunhilde Wirth; Eckhard Schoenau; Bernd Wollnik; Joris A Veltman; Alexander Hoischen; Christian Netzer
Journal:  Am J Hum Genet       Date:  2011-02-25       Impact factor: 11.025

5.  Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.

Authors:  Benjamin P Sinder; Joseph D Salemi; Michael S Ominsky; Michelle S Caird; Joan C Marini; Kenneth M Kozloff
Journal:  Bone       Date:  2014-10-23       Impact factor: 4.398

Review 6.  Causes, mechanisms and management of paediatric osteoporosis.

Authors:  Outi Mäkitie
Journal:  Nat Rev Rheumatol       Date:  2013-04-16       Impact factor: 20.543

7.  Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.

Authors:  J A Meganck; D L Begun; J D McElderry; A Swick; K M Kozloff; S A Goldstein; M D Morris; J C Marini; M S Caird
Journal:  Bone       Date:  2013-06-14       Impact factor: 4.398

8.  Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta.

Authors:  Jerry K Y Chan; Cecilia Götherström
Journal:  Front Pharmacol       Date:  2014-10-09       Impact factor: 5.810

9.  Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.

Authors:  Changgui Shi; Bin Sun; Chao Ma; Huiqiao Wu; Rui Chen; Hailong He; Ying Zhang
Journal:  Biomed Res Int       Date:  2021-01-08       Impact factor: 3.411

10.  Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice.

Authors:  Motoki Isawa; Akiko Karakawa; Nobuhiro Sakai; Saki Nishina; Miku Kuritani; Masahiro Chatani; Takako Negishi-Koga; Masashi Sato; Mitsuko Inoue; Yukie Shimada; Masamichi Takami
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.